We use cookies for a better user experience. Read our Privacy Policy

I Agree

Cardiac Arrest Treatment Market Insights, 2019-2027

Cardiac Arrest Treatment Market (Treatment - Drugs and Medical Devices; Sales Channel - Hospitals, Independent Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Global Cardiac Arrest Treatment Market – An Overview

World over cardiovascular diseases are seeing an increase in incidence. Additionally, certain underlying issues such as agonal breathing or apnea, which are known to cause cardiac arrest, are seeing an increase in numbers of people affected. Some of the reasons include lifestyle choices – alcohol and tobacco use, lack of exercise and a hectic work schedule.

As per Transparency Market Research, this will lead to growth in the global cardiac arrest treatment market over the forecast period of 2019 to 2020. A number of factors would underlie this growth and lead to generation of lucrative growth opportunities. Besides, they will pull up the market worth by a considerable value.

To understand what is driving the market forward, it is significant to note the following:

  • World over, geriatric population is seeing an increase in numbers. The year 2018 saw history being created with number of people in the geriatric bracket of 65 and above crossed number of children. The age bracket of the latter is below 6. By the year 2050, numbers will grow further in the former. Worldwide, one in every six and in North America and Europe, one in every four people will fall in the age group of 65 and above. This age group is susceptible to cardiac arrest.
  • Risk of CVD increases with certain diseases such as diabetes and conditions such as hypertension, hyperlipidaemia, and others. And, it is pertinent to note here that an increase in incidence of these will lead to a high risk for CVD, paving way for growth in the global cardiac arrest treatment market over the forecast period. Note that the number one cause of deaths in the world is CVD.

Cardiac Arrest Treatment Market - Snapshot

Cardiac arrest is defined as a sudden and abrupt loss of heart function, consciousness, and apnea or agonal breathing. It is a heterogeneous condition in terms of underlying pathology. It results from an electrical disturbance in the heart because of a problem with electrical signals. The disturbance leads to disruption in pumping action and stoppage of blood flow to the body. Cardiac arrest is often fatal. If appropriate steps are not taken immediately, sudden cardiac arrest can lead to death. The most common cause of a cardiac arrest is abnormal heart rhythm such as ventricular tachycardia or ventricular fibrillation. Other causes of cardiac arrest include thickened heart muscles (cardiomyopathy), heart medications, electrical abnormalities, blood vessel abnormalities, recreational drug use, and scarring of the heart tissue.

cardiac arrest treatment market

Obesity, diabetes mellitus, smoking, high cholesterol, high blood pressure, and sedentary lifestyles are the primary causes of heart failure and cardiac arrest. Rise in the number of people afflicted by these diseases is projected to drive demand for cardiac arrest treatment. According to the American Heart Association’s 2017 Heart Diseases and Stroke Statistics update, the number of people diagnosed with heart failure is increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with heart failure. There are 22 million people living with congestive heart failure across the world and additional 2 million people are diagnosed every year. According to the American Heart Association, congestive heart failure is one of the leading causes of death in the U.S., accounting for 8.5% of the total population. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths occur due to sudden cardiac arrest across the globe each year. Sudden cardiac death accounts for about 20% of all mortalities in the West. According to the U.S. National Library of Medicine of the National Institutes of Health, 40% to 50% of all cardiovascular deaths are sudden cardiac deaths (SCDs) and nearly 80% of these are caused by ventricular tachyarrhythmia. Therefore, about 6 million sudden cardiac deaths occur each year due to ventricular tachyarrhythmia. The overall prevalence of first degree atrioventricular block among the adult population in the U.S. is 3.7%. Prevalence of atrioventricular block is higher in patients with coronary heart diseases. Dual CRT pacemakers are implanted due to symptomatic bradycardia, which is caused by sick sinus syndrome or atrioventricular block or both. Untreated atrioventricular block will not only lead to heart failure, but also sudden cardiac death. However, stringent regulations for medical devices required for the treatment of cardiac arrest are expected to restrain the market during the forecast period.

The global cardiac arrest treatment market has been segmented based on treatment, sales channel, and region. In terms of treatment, the medical devices segment held major market share in 2018 and the trend is projected to continue during the forecast period. The beta blockers sub-segment is anticipated to dominate the drugs segment from 2019 to 2027. In terms of sales channel, the hospitals segment is likely to lead the global cardiac arrest treatment market during the forecast period.

Geographically, North America dominated the global cardiac arrest treatment market in 2018, accounting for the largest share. The region was the largest market for cardiac arrest treatment due to high adoption rate of CRT for cardiac arrest treatment among cardiologists and heart specialists and presence of large number of AED centers. Moreover, increase in incidence of cardiovascular disorders and advancements in medical devices for the treatment of cardiac arrest drive the cardiac arrest treatment market in North America. The market in Asia Pacific is expected to expand at a high CAGR from 2019 to 2027. Asia Pacific comprises major economies such as China, Japan, India, Australia, South Korea, and New Zealand. The cardiac arrest treatment market in Asia Pacific is growing rapidly compared to Europe and North America, which have shown stagnant growth in the past few years. Factors contributing to strong market growth in Asia Pacific are increase in incidence of sudden cardiac arrest (SCA), large patient base, rise in purchase of AEDs for organizational and corporate defibrillation programs, over the counter availability of AEDs, increase in disposable income, and subsequent spending on health care.

Key players operating in the global cardiac arrest treatment market include Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

The global cardiac arrest treatment market has been segmented as below:

Treatment

  • Drugs
    • Vasopressors
    • Anti-arrhythmic Drugs
    • Anticholinergic Drugs
    • Corticosteroids
    • Fibrinolytic Drugs
    • Beta Blockers
    • Others (sodium bicarbonate, crystalloids, colloids, etc.)
  • Medical Devices
    • Defibrillators
    • Cardiac Resynchronization Therapy (CRT)
    • Others

Sales Channel

  • Hospitals
  • Independent Pharmacies
  • Others

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Cardiac Arrest Treatment Market Insights, 2019-2027

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of Cell Expansion Market?

The global Cell Expansion Market was worth US$ US$7.7 bn and is projected to reach a value of US$26 bn by the end of 2024

What is the anticipated CAGR of the Cell Expansion Market in the forecast period?

Cell Expansion Market is anticipated to grow at a CAGR of 14.70% during the forecast period

Which region is expected to project the highest market share in the global Cell Expansion Market?

North America accounted for a major share of the global Cell Expansion Market

What are the key driving factors for the growth of the Cell Expansion Market?

Rising onus on the innovative work exercises on the cell-based treatments and rising GMP accreditations for creation offices for cell treatment are likewise significant for driving the development of the worldwide cell expansion market

Who are the key players in the global Cell Expansion Market?

Key players in the global Cell Expansion Market include Cell Signaling Technology, Inc., Terumo Corporation, GE Healthcare, STEMCELL Technologies, Takara Bio, Inc., Bio-Techne (R&D Systems), Octane Biotech, Inc., Dickinson and Company, Merck Millipore (Merck KGaA), Corning Incorporated, Eppendorf AG, PeproTech, Inc., Danaher Corporation (Pall Corporation), Lonza Group, Becton

1. Preface 
      1.1. Report Scope and Market Segmentation 
      1.2. Research Highlights

2. Assumptions and Research Methodology 
      2.1. Assumptions and Acronyms Used
      2.2. Research Methodology

3. Executive Summary
      3.1. Global Cardiac Arrest Treatment Market Size (US$ Mn) and Distribution, by Region, 2019 and 2027
      3.2. Global Cardiac Arrest Treatment Market: Market Snapshot

4. Market Overview
      4.1. Global Cardiac Arrest Treatment Market: Treatment Overview 
      4.2. Global Cardiac Arrest Treatment Market: Key Industry Developments
      4.3. Market Dynamics
      4.4. Drivers and Restraints Snapshot Analysis
      4.5. Drivers
             4.5.1. Rise in prevalence of congestive heart failure (CHF) 
             4.5.2. Government initiatives
      4.6. Restraints
             4.6.1. Low availability of cardiac arrest treatment in emerging countries
             4.6.2. Growth of the generic drugs industry
      4.7. Opportunities
      4.8. Global Cardiac Arrest Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights
      5.1. Incidence Rate of Cardiac Arrest In Key Countries
      5.2. Technological Advancements in Medical Devices for Cardiac Arrest Treatment 
      5.3. Treatment Usage Pattern (Three-Phase Model of Cardiac Arrest)
      5.4. Promising Treatments in Clinical Development: Cardiac Arrest 
      5.5. Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
      5.6. Key Merger and Acquisition
      5.7. Research and Development Strategies for Key Companies 
      5.8. Pipeline Analysis for Cardiac Arrest Therapeutics

6. Global Cardiac Arrest Treatment Market Analysis, by Treatment
      6.1. Introduction
      6.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             6.2.1. Drugs
                      6.2.1.1. Vasopressors
                      6.2.1.2. Anti-arrhythmic Drugs
                      6.2.1.3. Anticholinergic Drugs
                      6.2.1.4. Corticosteroids
                      6.2.1.5. Fibrinolytic Drugs
                      6.2.1.6. Beta Blockers
                      6.2.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             6.2.2. Medical Devices
                      6.2.2.1. Defibrillators
                      6.2.2.2. Cardiac Resynchronization Therapy (CRT)
                      6.2.2.3. Others
      6.3. Global Cardiac Arrest Treatment Market Analysis, by Treatment
      6.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Treatment

7. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
      7.1. Introduction
      7.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
             7.2.1. Hospitals 
             7.2.2. Independent Pharmacies
             7.2.3. Others
      7.3. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
      7.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Sales Channel

8. Global Cardiac Arrest Treatment Market Analysis, by Region
      8.1. Global Cardiac Arrest Treatment Market Size and Forecast, by Region, 2017–2027 
             8.1.1. North America
             8.1.2. Europe
             8.1.3. Asia Pacific
             8.1.4. Latin America
             8.1.5. Middle East & Africa
      8.2. Global Cardiac Arrest Treatment Market Analysis, by Region
      8.3. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Region

9. North America Cardiac Arrest Treatment Market Analysis
      9.1. North America Cardiac Arrest Treatment Market 
      9.2. North America Cardiac Arrest Treatment Market Overview
      9.3. North America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             9.3.1. Drugs
                      9.3.1.1. Vasopressors
                      9.3.1.2. Anti-arrhythmic Drugs
                      9.3.1.3. Anticholinergic Drugs
                      9.3.1.4. Corticosteroids
                      9.3.1.5. Fibrinolytic Drugs
                      9.3.1.6. Beta Blockers
                      9.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             9.3.2. Medical Devices
                      9.3.2.1. Defibrillators
                      9.3.2.2. Cardiac Resynchronization Therapy (CRT)
                      9.3.2.3. Others 
      9.4. North America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel 
             9.4.1. Hospitals 
             9.4.2. Independent Pharmacies
             9.4.3. Others
      9.5. North America Cardiac Arrest Treatment Market Forecast, by Country
             9.5.1. U.S.
             9.5.2. Canada
      9.6. North America Cardiac Arrest Treatment Market Attractiveness Analysis 
             9.6.1. By Treatment
             9.6.2. By Sales Channel
             9.6.3. By Country

10. Europe Cardiac Arrest Treatment Market Analysis
      10.1. Europe Cardiac Arrest Treatment Market 
      10.2. Europe Cardiac Arrest Treatment Market Overview
      10.3. Europe Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             10.3.1. Drugs
                      10.3.1.1. Vasopressors
                      10.3.1.2. Anti-arrhythmic Drugs
                      10.3.1.3. Anticholinergic Drugs
                      10.3.1.4. Corticosteroids
                      10.3.1.5. Fibrinolytic Drugs
                      10.3.1.6. Beta Blockers
                      10.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             10.3.2. Medical Devices
                      10.3.2.1. Defibrillators
                      10.3.2.2. Cardiac Resynchronization Therapy (CRT)
                      10.3.2.3. Others 
      10.4. Europe Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel 
             10.4.1. Hospitals 
             10.4.2. Independent Pharmacies
             10.4.3. Others
      10.5. Europe Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
             10.5.1. U.K.
             10.5.2. France
             10.5.3. Germany
             10.5.4. Spain
             10.5.5. Italy
             10.5.6. Rest of Europe
      10.6. Europe Cardiac Arrest Treatment Market Attractiveness Analysis 
             10.6.1. By Treatment
             10.6.2. By Sales Channel
             10.6.3. By Country/Sub-region

11. Asia Pacific Cardiac Arrest Treatment Market Analysis
      11.1. Asia Pacific Cardiac Arrest Treatment Market Key Findings
      11.2. Asia Pacific Cardiac Arrest Treatment Market Overview
      11.3. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             11.3.1. Drugs
                      11.3.1.1. Vasopressors
                      11.3.1.2. Anti-arrhythmic Drugs
                      11.3.1.3. Anticholinergic Drugs
                      11.3.1.4. Corticosteroids
                      11.3.1.5. Fibrinolytic Drugs
                      11.3.1.6. Beta Blockers
                      11.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             11.3.2. Medical Devices
                      11.3.2.1. Defibrillators
                      11.3.2.2. Cardiac Resynchronization Therapy (CRT)
                      11.3.2.3. Others 
      11.4. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel 
             11.4.1. Hospitals 
             11.4.2. Independent Pharmacies
             11.4.3. Others
      11.5. Asia Pacific Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
             11.5.1. China
             11.5.2. India
             11.5.3. Japan
             11.5.4. Australia & New Zealand
             11.5.5. Rest of Asia Pacific
      11.6. Asia Pacific Cardiac Arrest Treatment Market Attractiveness Analysis 
             11.6.1. By Treatment
             11.6.2. By Sales Channel
             11.6.3. By Country/Sub-region

12. Latin America Cardiac Arrest Treatment Market Analysis
      12.1. Latin America Cardiac Arrest Treatment Market Key Findings
      12.2. Latin America Cardiac Arrest Treatment Market Overview
      12.3. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             12.3.1. Drugs
                      12.3.1.1. Vasopressors
                      12.3.1.2. Anti-arrhythmic Drugs
                      12.3.1.3. Anticholinergic Drugs
                      12.3.1.4. Corticosteroids
                      12.3.1.5. Fibrinolytic Drugs
                      12.3.1.6. Beta Blockers
                      12.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             12.3.2. Medical Devices
                      12.3.2.1. Defibrillators
                      12.3.2.2. Cardiac Resynchronization Therapy (CRT)
                      12.3.2.3. Others 
      12.4. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel 
             12.4.1. Hospitals 
             12.4.2. Independent Pharmacies
             12.4.3. Others
      12.5. Latin America Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
             12.5.1. Brazil
             12.5.2. Mexico
             12.5.3. Rest of Latin America
      12.6. Latin America Cardiac Arrest Treatment Market Attractiveness Analysis 
             12.6.1. By Treatment
             12.6.2. By Sales Channel
             12.6.3. By Country/Sub-region

13. Middle East & Africa Cardiac Arrest Treatment Market Analysis
      13.1. Middle East & Africa Cardiac Arrest Treatment Market 
      13.2. Middle East & Africa Cardiac Arrest Treatment Market Overview
      13.3. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Treatment
             13.3.1. Drugs
                      13.3.1.1. Vasopressors
                      13.3.1.2. Anti-arrhythmic Drugs
                      13.3.1.3. Anticholinergic Drugs
                      13.3.1.4. Corticosteroids
                      13.3.1.5. Fibrinolytic Drugs
                      13.3.1.6. Beta Blockers
                      13.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
             13.3.2. Medical Devices
                      13.3.2.1. Defibrillators
                      13.3.2.2. Cardiac Resynchronization Therapy (CRT)
                      13.3.2.3. Others 
      13.4. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel 
             13.4.1. Hospitals 
             13.4.2. Independent Pharmacies
             13.4.3. Others
      13.5. Middle East & Africa Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
             13.5.1. GCC Countries
             13.5.2. South Africa
             13.5.3. Rest of Middle East & Africa
      13.6. Middle East & Africa Cardiac Arrest Treatment Market Attractiveness Analysis 
             13.6.1. By Treatment
             13.6.2. By Sales Channel
             13.6.3. By Country/Sub-region

14. Competition Landscape
      14.1. Company Profiles
             14.1.1. Amgen, Inc.
                      14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.1.2. Financials
                      14.1.1.3. Recent Developments
                      14.1.1.4. Strategy
             14.1.2. Pfizer, Inc.
                      14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.2.2. Financials
                      14.1.2.3. Recent Developments
                      14.1.2.4. Strategy
             14.1.3. Johnson & Johnson 
                      14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.3.2. Financials
                      14.1.3.3. Recent Developments
                      14.1.3.4. Strategy
             14.1.4. Novartis AG
                      14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.4.2. Financials
                      14.1.4.3. Recent Developments
                      14.1.4.4. Strategy
             14.1.5. Bristol-Myers Squibb Company 
                      14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.5.2. Financials
                      14.1.5.3. Recent Developments
                      14.1.5.4. Strategy
             14.1.6. Abbott
                      14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.6.2. Financials
                      14.1.6.3. Recent Developments
                      14.1.6.4. Strategy
             14.1.7. Bayer AG
                      14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.7.2. Financials
                      14.1.7.3. Recent Developments
                      14.1.7.4. Strategy
             14.1.8.  Koninklijke Philips N.V
                      14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.8.2. Financials
                      14.1.8.3. Recent Developments
                      14.1.8.4. Strategy
             14.1.9. GE Healthcare
                      14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.9.2. Financials
                      14.1.9.3. Recent Developments
                      14.1.9.4. Strategy
             14.1.10. Physio-Control, Inc. (Stryker)
                      14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.10.2. Financials
                      14.1.10.3. Recent Developments
                      14.1.10.4. Strategy
             14.1.11. Boston Scientific Corporation
                      14.1.11.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.11.2. Financials
                      14.1.11.3. Recent Developments
                      14.1.11.4. Strategy
             14.1.12. Cardiac Science Corporation (Aurora Capital Group)
                      14.1.12.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.12.2. Financials
                      14.1.12.3. Recent Developments
                      14.1.12.4. Strategy
             14.1.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
                      14.1.13.1. Overview (HQ, Employee Strength, Business Segments)
                      14.1.13.2. Financials
                      14.1.13.3. Recent Developments
                      14.1.13.4. Strategy

List of Tables

TABLE 1 Prevalence Rate of Cardiac Arrest In Key Countries
TABLE 2 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 2 Drugs
TABLE 3 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 3 and Phase 4 Drugs
TABLE 4 Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
TABLE 5 Cost incurred to cardiac arrest patients
TABLE 6 Key Merger and Acquisition (1/2)
TABLE 7 Key Merger and Acquisition (2/2)
TABLE 8 Percent of Heart Failure Trials, by Phase and Location
TABLE 9 Percent of Heart Failure Trials, by Phase and Companies
TABLE 10 Pipeline Analysis for Cardiovascular Disorders Therapeutics (1/5)
TABLE 11 Pipeline Analysis for Cardiovascular Disorders Therapeutics (2/5)
TABLE 12 Pipeline Analysis for Cardiovascular Disorders Therapeutics (3/5)
TABLE 13  Pipeline Analysis for Cardiovascular Disorders Therapeutics (4/5)
TABLE 14 Pipeline Analysis for Cardiovascular Disorders Therapeutics (5/5)
TABLE 15 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 16 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 17 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 18 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 19 Global Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
TABLE 20 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
TABLE 21 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 22 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 23 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 24 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 25 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 26 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 27 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 28 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 29 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 30 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 31 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 32 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 33 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 34 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 35 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 36 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 37 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 38 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 39 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 40 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 41 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 42 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 43 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 44 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

List of Figures

FIG. 1 Global Cardiac Arrest Treatment Market Size (US$ Mn), 2017 and 2026
FIG. 2 Global Cardiac Arrest Treatment Market Snapshot
FIG. 3 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, 2017–2027
FIG. 4 Global Cardiac Arrest Treatment Market
FIG. 5 Global Cardiac Arrest Treatment Market
FIG. 6 Global Cardiac Arrest Treatment Market
FIG. 7 Global Cardiac Arrest Treatment Market
FIG. 8 Global Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 9 Global Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 10 Global Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 11 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Vasopressors, 2017–2027
FIG. 12 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Anti-arrhythmic Drugs, 2017–2027
FIG. 13 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Anticholinergic Drugs, 2017–2027
FIG. 14 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2027
FIG. 15 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Fibrinolytic Drugs, 2017–2027
FIG. 16 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Beta Blockers, 2017–2027
FIG. 17 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 18 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Defibrillators, 2017–2027
FIG. 19 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Cardiac Resynchronization Therapy (CRT), 2017–2027
FIG. 20 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 21 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Drugs, 2017–2025
FIG. 22 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Medical Devices, 2017-2025
FIG. 23 Global Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2017 and 2025
FIG. 24 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Hospital, 2017–2027
FIG. 25 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Independent Pharmacies, 2017–2027
FIG. 26 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 27 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Sales Channel 2017–2025
FIG. 28 Global Cardiac Arrest Treatment Market Value Share, by Region, 2018 and 2027
FIG. 29 Global Cardiac Arrest Treatment Market Attractiveness, by Region, 2019–2027
FIG. 30 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2019–2027
FIG. 31 North America Cardiac Arrest Treatment Market Value Share, by Country, 2018 and 2027
FIG. 32 North America Cardiac Arrest Treatment Market Attractiveness, by Country, 2019–2027
FIG. 33 North America Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 34 North America Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 35 North America Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 36 North America Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 37 North America Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 38 North America Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 39 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 40 Europe Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 41 Europe Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 42 Europe Cardiac Arrest Treatment Market Value Share, by Treatment, 2018 and 2027
FIG. 43 Europe Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 44 Europe Cardiac Arrest Treatment Market Value Share, by Drugs, 2018 and 2027
FIG. 45 Europe Cardiac Arrest Treatment Market Value Share, by Medical Devices, 2018 and 2027
FIG. 46 Europe Cardiac Arrest Treatment Market Value Share, by Sales Channel, 2018 and 2027
FIG. 47 Europe Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 48 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2019–2027
FIG. 49 Asia Pacific Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 50 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 51 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 52 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 53 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 54 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 55 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 56 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 57 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 58 Latin America Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 59 Latin America Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 60 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 61 Latin America Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 62 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 63 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 64 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 65 Latin America Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 66 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 67 Middle East & Africa Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 68 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 69 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 70 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 71 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 72 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 73 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 74 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 75 Global Cardiac Arrest Treatment Drugs Market Share Analysis, by Company (2018)
FIG. 76 Global Cardiac Arrest Treatment Medical Devices Market Share Analysis, by Company (2018)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

746

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved